Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 563-573

  Penzner, Julie B ^a   Dudas, Melissa ^b   Saito, Ema ^b   Olshanskiy, Vladimir ^b   Parikh, Umesh H ^b   Kapoor, Sandeep ^b   Chekuri, Raja ^b   Gadaleta, Dominick ^b   Avedon, Jennifer ^b   Sheridan, Eva M ^b   Randell, Jane ^b   Malhotra, Anil K ^b,c,d   Kane, John M ^b,c,d   Correll, Christoph U ^b,c,d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; CLOZAPINE; DEXAMPHETAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPHENIDATE; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADOLESCENT; ADULT; AGGRESSION; ANTICHOLINERGIC EFFECT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BLOOD LEVEL; BODY MASS; CHILD; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; GILLES DE LA TOURETTE SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; IMPULSE CONTROL DISORDER; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTERMITTENT EXPLOSIVE DISORDER; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MOOD DISORDER; OPPOSITIONAL DEFIANT DISORDER; PRESCHOOL CHILD; PROLACTIN ABNORMALITY; SCHOOL CHILD; SEDATION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 70449104405     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0051     Document Type: Article

References (38)

1. Aman MG, DeSmedt G, Derivan A, Lyons B, Findling RL, the Risperidone Disruptive Behavior Study Group: Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. Am J Psychiatry 159:1337-1346, 2002.
2. Aman MG, Binder C, Turgay A: Risperidone effects in the presence= absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243-254, 2004.
3. American Psyschiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition(DMX-IV). Washington (DC): American Psychiatric Association, 1994.
4. Arcelus J, Vostanis P: Child psychiatric disorders among primary mental health service attenders. Br J Gen Pract 53:214-216, 2003. (Pubitemid 36300905)
5. Armenteros JL, Lewis JE, Davalos M: Risperidone augmentation for treatment-resistant aggression in attention-deficit=hyperactivity disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46:558-565, 2007.
6. August GJ, Realmuto FM, MacDonald AW III, Nugent SM, Crosby R: Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior. J Abnorm Child Psychol 5:571-595, 1996.
7. Burke M, Sebastian CS. Treatment of clozapine sedation. Am J Psychiatry 150:1900-1901, 1993.
8. Calarge C, Acion L, Kuperman S, Tansey M, Schlechte J. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19:101-109, 2009.
9. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008a.
10. Correll CU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69:26-36, 2008b.
11. Correll CU: Monitoring and management of antipsychotic-related metabolic and endocrine adverse effects in children and adolescents. Int Rev Psychiatry 20:195-201, 2008c.
12. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
13. Correll CU, Penzner JB, Parikh UH, Mughal TB, Javed T, Carbon M, Malhotra AK: Recognizing and monitoring adverse events of second- generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177-206, 2006.
14. Correll CU, Penzner JB, Lencz T, Auther A, Smith C, Kane JM, Malhotra AK, Cornblatt BA: Early identification and high risk strategies for bipolar disorder. Bipolar Disord 9:324-338, 2007.
15. Ezpeleta L, Keller G, Erkanli A, Costello EJ, Angold A: Epidemiology of psychiatric disability in childhood and adolescence. J Child Psychol Psychiatry 42:901-914, 2001.
16. Faraone SV, Biederman J, Morley CP, Spencer TJ: Effect of stimulants on height and weight: A review of the literature. J Am Acad Child Adolesc Psychiatry 47:994-1009, 2008.
17. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
18. Guy W: ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education and Welfare publicationABM76-338. Washington (DC): US Government Printing Office, 223-241, 1976.
19. HaasM, Karcher K, Pandina GJ: Treating disruptive behavior disorders with risperidone: A 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol 18:337-345, 2008.
20. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M: Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trials. Eur Child Adolesc Psychiatry 16:104-120, 2007.
21. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW: Quetiapine addition in methylphenidate treatmentresistant adolescents with comorbid attention-deficit=hyperactivity disorder, conduct=oppositional-defiant disorder, and aggression: A prospective, open-label study. J Child Adolesc Psychopharm 17: 334-347, 2007.
22. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among US adolescents: A population-based study. Diabetes Care 29:2427-2432, 2006.
23. Loeber R, Burke JD, Lahey BB, Winters A, Zera M: Oppositional defiant and conduct disorder: A review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry 39:1468-1484, 2000.
24. Makela EH, Miller K, Cutlip WD: Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 64:485-486, 2003.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985.
26. Miklowitz DJ, Chang KD: Prevention of bipolar disorder in at-risk children: Theoretical assumptions and empirical foundations. Dev Psychopathol 20:881-897, 2008.
27. Miller SC: Methylphenidate for clozapine sedation. Am J Psychiatry 153:1231-1232, 1996.
28. Nock MK, Kazdin AE, Hiripi E, Kessler RC: Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: Results from the national comorbidity survey replication. J Child Psychol Psychiatry 48:703-713, 2007.
29. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006.
30. Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145-161, 2003. (Pubitemid 39610594)
31. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS. Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. J Can Acad Child Adolesc Psychiatry 15:27-39, 2006.
32. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M: Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit=hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642-657, 2006.
33. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, Macintyre II JC, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003. (Pubitemid 39610593)
34. Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswaraiah H, Gunduz- Bruce H, Schooler NR. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66:839-843, 2005.
35. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
36. Snyder R, Turgay A, Aman M, Binder C, Fisman S: The Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
37. The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086, 1999.
38. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.